Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
Determine the effects of Apitox add-on therapy on the progression of disability in all forms
of multiple sclerosis (MS) utilizing the Expanded Disability Status Scale (EDSS) and the MS
Functional Composite (MSFC) measure. b. Evaluate the safety and tolerability of add-on Apitox
therapy for the treatment of patients with all forms of MS: relapsing-remitting MS (RRMS),
primary progressive MS (PPMS) and secondary progressive MS (SPMS). The